SCHEMBL2599677

SCHEMBL2599677

O=C1COc2c(F)cccc2N1Cc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.64
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 1/20 0.48
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 1/20 0.47
TSHR P16473 2/20 0.45
BRD4 O60885 2/20 0.45
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
GSK3B P49841 2/20 0.42
DRD4 P21917 1/20 0.42
MAPT P10636 1/20 0.41
F2 P00734 1/20 0.41
PLG P00747 1/20 0.41
ELANE P08246 1/20 0.41
CTSG P08311 1/20 0.41
CMA1 P23946 1/20 0.41
CTRC Q99895 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14309629 0.86 HTR6 (0.64) HTR6L3MBTL1POLBALDH1A1KDM4E
SCHEMBL4676101 0.84 HTR6 (0.65) HTR6L3MBTL1POLBALDH1A1KDM4E
SCHEMBL14302362 0.83 HTR6 (0.64) HTR6L3MBTL1POLBALDH1A1KDM4E
SCHEMBL4089857 0.80 DRD2 (0.43) HTR6POLBDRD4
SCHEMBL4676109 0.78 HTR6 (0.52) HTR6L3MBTL1ALDH1A1KDM4ETSHR
SCHEMBL4674593 0.78 HTR6 (0.74) HTR6L3MBTL1POLBALDH1A1KDM4E
SCHEMBL1136491 0.78 HTR6 (1.00) HTR6L3MBTL1POLB
SCHEMBL4674564 0.77 ALDH1A1 (0.51) HTR6L3MBTL1ALDH1A1TSHRKMT2A
SCHEMBL4677545 0.77 HTR6 (0.51) HTR6L3MBTL1POLBALDH1A1KDM4E
Hydrochloric Acid SCHEMBL4678621 0.77 HTR6 (0.98) HTR6L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3080115-B1 FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-05-08 EP disclosed
US-9868749-B2 Fused imidazole and pyrazole derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2018-01-16 US disclosed
EP-3080115-A1 FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2016-10-19 EP disclosed
US-20160297837-A1 Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity EVOTEC (UK) LTD. (GB) 2016-10-13 US disclosed
WO-2015086506-A1 FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
EP-2571872-B1 COMPOUNDS TREHERNE JOHNATHAN MARK (GB) 2014-12-31 EP disclosed
EP-2571872-B1 COMPOUNDS TREHERNE JOHNATHAN MARK (GB) 2014-12-31 EP disclosed
EP-2571872-A1 COMPOUNDS BTG International Limited (GB) 2013-03-27 EP disclosed
WO-2011144578-A1 COMPOUNDS SENEXIS LIMITED (GB) 2011-11-24 WO disclosed
WO-2011144578-A1 COMPOUNDS SENEXIS LIMITED (GB) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297837-A1 Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity TNF, TNFRSF1A, TNFRSF9 HTR6 2141/4885L3MBTL1 2895/4885POLB 3375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.